GB Sciences Announces the Appointment of John B. Davis as Executive VP and General Counsel
LAS VEGAS, April 12, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB:GBLX), a company that marries cutting edge cannabis cultivation and biopharmaceutical research and development, announced today that it has appointed John B. Davis as Executive Vice President, General Counsel – effective immediately.
In addition, Davis has been named President of GB Sciences Louisiana, LLC, the entity that will be responsible for the cultivation, extraction, processing, and production of therapeutic cannabis for qualifying patients under an agreement with the Louisiana State University (LSU) AgCenter. As a public institution of higher education, the LSU AgCenter’s partnership with GB Sciences represents a first in the therapeutic cannabis industry.
Davis joins GB Sciences from Baker, Donelson, Bearman, Caldwell & Berkowitz, PC, one of the nation’s largest law firms representing clients both nationally and internationally. Davis brings over 20 years of experience working directly with and advising C-Suite executives in a variety of industries and has developed a reputation for providing creative legal and legislative solutions to challenging problems.
John C. Poss, Chairman and Chief Executive Officer of GB Sciences, stated, “John has proven extremely successful at every endeavor he has undertaken, and we are proud to have him join our management team.”
“I am honored to join a dedicated and experienced management team at GB Sciences and look forward to contributing to the continued growth and success of the Company,” commented Davis.
Davis holds a Juris Doctorate from Loyola University School of Law and a bachelor’s degree from Louisiana State University.
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
Tom Arcuragi, EVP, firstname.lastname@example.org